Global Custom Market Research Reports Provider Company

phone

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2018

  • Published Date: 13 Nov 2018
  • Number of Pages: 50
  • Category: Pharmaceuticals
  • Country: Global
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2018

Summary

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L co-stimulation.

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) pipeline Target constitutes close to 8 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 5 respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease, Musculoskeletal Disorders, Ophthalmology and Toxicology which include indications Rheumatoid Arthritis, Graft Versus Host Disease (GVHD), Multiple Sclerosis, Solid Tumor, Acute Renal Failure (ARF) (Acute Kidney Injury), B-Cell Chronic Lymphocytic Leukemia, Gastrointestinal Radiation Toxicity, Kidney Transplant Rejection, Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Psoriatic Arthritis, Sepsis, Skin And Soft Tissue Infections, Stem Cell Transplantation and Uveitis.

The latest report T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2018, outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
- The report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects
- The report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Publisher Name : Global Markets Direct

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Overview
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Companies Involved in Therapeutics Development
Atox Bio Ltd
Five Prime Therapeutics Inc
Imugene Ltd
Johnson & Johnson
TheraMAB LLC
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drug Profiles
ALPN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALPN-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FPT-155 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FR-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target CD278, CD28 and HER2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reltecimod sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAB-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD28 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Dormant Products
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Discontinued Products
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Product Development Milestones
Featured News & Press Releases
Oct 22, 2018: Alpine Immune Sciences lead program ALPN-101 demonstrates preclinical activity in inflammatory arthritis and neurological inflammation
Oct 04, 2018: Alpine Immune Sciences to Present at Society for Immunotherapy of Cancer 33rd Annual Meeting
Sep 25, 2018: Atox Bio announces Independent Safety Monitoring Committee recommendation to continue Phase 3 study of Reltecimod in necrotizing soft tissue infections
Sep 24, 2018: Alpine Immune Sciences Announces Upcoming Scientific Presentations
Sep 11, 2018: OSE Immunotherapeutics announces issuance of a European Patent protecting FR104, CD28-antagonist immunotherapy
Aug 22, 2018: OSE Immunotherapeutics publishes new efficacy data on FR104, CD28-antagonist immunotherapy
May 29, 2018: Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)
Apr 17, 2018: Alpine Immune Sciences announces preclinical data demonstrating ALPN-202 eliminates tumors and creates persistent tumor resistance in a murine cancer model
Dec 09, 2017: Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease
Dec 06, 2017: Alpine Immune Sciences Announces Preclinical Results Showing Novel Immuno-Oncology Co stimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells
Nov 06, 2017: Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation
Oct 30, 2017: Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155
Oct 19, 2017: OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy
Oct 18, 2017: Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Sep 25, 2017: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of Reltecimod for Necrotizing Soft Tissue Infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Atox Bio Ltd, H2 2018
Pipeline by Five Prime Therapeutics Inc, H2 2018
Pipeline by Imugene Ltd, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by TheraMAB LLC, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List Of Figures


Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Aphthous Ulcers (Canker Sores) Global Clinical Trials Review, H2, 2018 GlobalDatas clinical trial report, Aphthous Ulcers (Canker Sores) Global Clinical Trials Review, H2, 2018 provides an overview of Aphthous Ulcers (Canker

View Report

Aphasia Global Clinical Trials Review, H2, 2018 GlobalDatas clinical trial report, Aphasia Global Clinical Trials Review, H2, 2018 provides an overview of Aphasia clinical trials scenario. This report provides top line

View Report

Aortic Valve Stenosis Global Clinical Trials Review, H2, 2018 GlobalDatas clinical trial report, Aortic Valve Stenosis Global Clinical Trials Review, H2, 2018 provides an overview of Aortic Valve Stenosis clinical trials

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports